CNMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Conmed Corp (CNMD) is not a strong buy for a beginner, long-term investor at this time. The company's financial performance shows declining net income and EPS, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. Analysts have lowered price targets, and the stock lacks recent momentum or strong sentiment indicators. It is better to hold off on investing until more favorable conditions emerge.
The MACD is slightly positive at 0.33, indicating mild bullish momentum, but it is contracting. RSI is neutral at 56.882, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in price movement. The stock is trading near its pivot level of 40.326, with resistance at 43.152 and support at 37.499.
The exit from gastroenterology product lines is expected to improve gross margins in the long term.
No recent news or significant trading trends from hedge funds or insiders. No recent congress trading data.
In Q4 2025, revenue increased by 7.88% YoY to $373.2M, but net income dropped by 50.41% to $16.7M. EPS also fell by 50% to $0.54, and gross margin declined slightly to 56.59% (-1.29% YoY).
BofA lowered the price target from $65 to $52, maintaining a Neutral rating. The exit from gastroenterology product lines is seen as accretive to gross margins but dilutive to earnings in 2026.
